{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:57:07Z","timestamp":1788904627263,"version":"build-2803163510"},"reference-count":113,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020581","name":"AIRC Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.dld.2026.02.020","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:37:03Z","timestamp":1773664623000},"page":"581-590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Toward precision chemotherapy in pancreatic ductal adenocarcinoma: molecular, transcriptomic and clinical determinants"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0019-8753","authenticated-orcid":false,"given":"Gabriele","family":"Capurso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-6896","authenticated-orcid":false,"given":"Ingrid","family":"Garajova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5113-2793","authenticated-orcid":false,"given":"Luigi Carmine","family":"Leta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Dusetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Reni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dld.2026.02.020_bib0001","first-page":"5","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.dld.2026.02.020_bib0002","first-page":"315","article-title":"Pancreatic cancer biomarkers: recent progress and challenges","volume":"15","author":"Partyka","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.dld.2026.02.020_bib0003","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"ESMO Guidelines Committee. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2026.02.020_bib0004","series-title":"NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma. version 2.2025","year":"2025"},{"issue":"2","key":"10.1016\/j.dld.2026.02.020_bib0005","first-page":"156","article-title":"Patterns and timing of recurrence after surgery for pancreatic ductal adenocarcinoma: a multicenter analysis","volume":"26","author":"Stoop","year":"2025","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.dld.2026.02.020_bib0006","first-page":"4211","article-title":"Recurrence patterns and survival after neoadjuvant therapy in pancreatic cancer","volume":"31","author":"Schouten","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.dld.2026.02.020_bib0007","first-page":"301","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline-resectable pancreatic cancer (PREOPANC trial): long-term results","volume":"26","author":"Janssen","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.02.020_bib0008","article-title":"Total neoadjuvant FOLFIRINOX versus gemcitabine-based chemoradiotherapy in resectable pancreatic cancer (PREOPANC-2): a randomized phase III trial","author":"Unno","year":"2025","journal-title":"Ann Surg"},{"key":"10.1016\/j.dld.2026.02.020_bib0009","series-title":"Preoperative mFOLFIRINOX versus paxg for stage i-iii resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2\u2009\u00d7\u20092 factorial phase 3 trial","author":"Reni","year":"2025"},{"issue":"10041","key":"10.1016\/j.dld.2026.02.020_bib0010","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer (JASPAC-01): a phase 3, open-label, randomized, non-inferiority trial","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.dld.2026.02.020_bib0011","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.dld.2016.11.010","article-title":"Borderline resectable pancreatic cancer: more than an anatomical concept","volume":"49","author":"Petrelli","year":"2017","journal-title":"Dig Liver Dis"},{"issue":"14","key":"10.1016\/j.dld.2026.02.020_bib0012","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: final results of CONKO-001","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"issue":"10073","key":"10.1016\/j.dld.2026.02.020_bib0013","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in pancreatic cancer (ESPAC-4): a multicentre, open-label, randomized, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.dld.2026.02.020_bib0014","first-page":"1220","article-title":"FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer (PRODIGE 24\/ACCORD 24): updated results of a phase 3 trial","volume":"40","author":"Conroy","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10041","key":"10.1016\/j.dld.2026.02.020_bib0015","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"JASPAC-01 trial: long-term follow-up results of S-1 versus gemcitabine as adjuvant chemotherapy for pancreatic cancer","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.dld.2026.02.020_bib0016","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.dld.2026.02.020_bib0017","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer (PRODIGE 4\/ACCORD 11)","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.dld.2026.02.020_bib0018","first-page":"317","article-title":"FOLFIRINOX versus gemcitabine in locally advanced pancreatic cancer: final results of the LAPACT study","volume":"10","author":"Hammel","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.dld.2026.02.020_bib0019","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2468-1253(18)30196-1","article-title":"Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial","volume":"3","author":"Reni","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"20","key":"10.1016\/j.dld.2026.02.020_bib0020","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1200\/JCO-24-02210","article-title":"PRODIGE 29-UCGI 26 (NEOPAN): A phase III randomized trial comparing chemotherapy with FOLFIRINOX or Gemcitabine in locally advanced pancreatic carcinoma","volume":"43","author":"Ducreux","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10409","key":"10.1016\/j.dld.2026.02.020_bib0021","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open- label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.dld.2026.02.020_bib0022","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1200\/JCO.2013.53.6995","article-title":"Second-line oxaliplatin-based chemotherapy following gemcitabine failure in advanced pancreatic cancer: results of CONKO-003","volume":"32","author":"Oettle","year":"2014","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.dld.2026.02.020_bib0023","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1200\/JCO.2016.68.5776","article-title":"PANCREOX: A randomized phase III study of modified FOLFOX6 versus infusional fluorouracil\/leucovorin in advanced pancreatic cancer after gemcitabine failure","volume":"34","author":"Gill","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2026.02.020_bib0024","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.dld.2026.02.020_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114226","article-title":"Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients","volume":"208","author":"Orsi","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2026.02.020_bib0026","doi-asserted-by":"crossref","DOI":"10.1002\/ueg2.70124","article-title":"Toward precision chemotherapy for pancreatic cancer guided by transcriptomic signatures. United","author":"Chanez","year":"2025","journal-title":"Eur Gastroenterol J"},{"issue":"4","key":"10.1016\/j.dld.2026.02.020_bib0027","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcac030","article-title":"The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping","volume":"4","author":"Lautizi","year":"2022","journal-title":"NAR Cancer"},{"issue":"11","key":"10.1016\/j.dld.2026.02.020_bib0028","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.cgh.2022.10.014","article-title":"Routine molecular profiling in both resectable and unresectable pancreatic adenocarcinoma: relevance of cytologic samples","volume":"21","author":"Redegalli","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.dld.2026.02.020_bib0029","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.3390\/cells9122561","article-title":"RNA extraction from endoscopic ultrasound-acquired tissue of pancreatic cancer is feasible and allows investigation of molecular features","volume":"9","author":"Archibugi","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.dld.2026.02.020_bib0030","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.1038\/s41467-025-60808-z","article-title":"Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial","volume":"16","author":"Knox","year":"2025","journal-title":"Nat Commun"},{"issue":"3-4","key":"10.1016\/j.dld.2026.02.020_bib0031","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/sj.bjc.6690097","article-title":"Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients","volume":"79","author":"Van Kuilenburg","year":"1999","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.dld.2026.02.020_bib0032","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"9","author":"Hendricks","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.dld.2026.02.020_bib0033","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1172\/JCI915","article-title":"Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes","volume":"101","author":"Iyer","year":"1988","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.dld.2026.02.020_bib0034","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/s41431-022-01243-2","article-title":"Dutch pharmacogenetics working group (DPWG) guideline for the gene\u2013drug interaction between UGT1A1and irinotecan","volume":"31","author":"Hulshof","year":"2022","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"10.1016\/j.dld.2026.02.020_bib0035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3892\/ol.2024.14845","article-title":"Intratumoural expression of dihydropyrimidine dehydrogenase is an independent prognostic factor in resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine","volume":"29","author":"Blomstrand","year":"2024","journal-title":"Onco Lett"},{"key":"10.1016\/j.dld.2026.02.020_bib0036","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6673125","article-title":"UGT1A Gene Family members serve as potential targets and prognostic biomarkers for pancreatic cancer","author":"Feng","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.dld.2026.02.020_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.clnu.2025.106573","article-title":"Impact of nutritional status on chemotherapy delivery and outcomes in advanced pancreatic cancer: A prospective multicenter study","volume":"57","author":"Kiriukova","year":"2026","journal-title":"Clin Nutr"},{"key":"10.1016\/j.dld.2026.02.020_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpg.2025.101991","article-title":"The exposome as a target for primary prevention and a tool for early detection of pancreatic cancer","volume":"74","author":"Lauri","year":"2025","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.dld.2026.02.020_bib0039","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.dld.2026.02.020_bib0040","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","article-title":"Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study","volume":"31","author":"Ueno","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.dld.2026.02.020_bib0041","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/bjc.2016.209","article-title":"Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma","volume":"115","author":"Reni","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.dld.2026.02.020_bib0042","first-page":"2021","article-title":"Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer","author":"Sugimoto","year":"2021","journal-title":"Fuku J Med Sc"},{"key":"10.1016\/j.dld.2026.02.020_bib0043","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-Paclitaxel plus Gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.dld.2026.02.020_bib0044","doi-asserted-by":"crossref","first-page":"902","DOI":"10.14740\/wjon1920","article-title":"The prevalence of 5-fluorouracil and capecitabine cardiotoxicity: A systematic review and meta-analysis","volume":"15","author":"Sapapsap","year":"2024","journal-title":"World J Oncol"},{"issue":"2","key":"10.1016\/j.dld.2026.02.020_bib0045","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1159\/000500242","article-title":"The spectrum of pulmonary toxicity in pancreatic cancer patients receiving gemcitabine combination chemotherapy","volume":"12","author":"Baig","year":"2019","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.dld.2026.02.020_bib0046","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Wang-Gillam","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.dld.2026.02.020_bib0047","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221141233","article-title":"A modified regimen of 21-day nab-Paclitaxel plus gemcitabine in locally advanced or metastatic pancreatic cancer: A retrospective real-world study","volume":"29","author":"Chang","year":"2022","journal-title":"Cancer Control"},{"issue":"2","key":"10.1016\/j.dld.2026.02.020_bib0048","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/1758834016676011","article-title":"A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis","volume":"9","author":"Ahn","year":"2017","journal-title":"The Adv Med Oncol"},{"key":"10.1016\/j.dld.2026.02.020_bib0049","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.03238","article-title":"Homologous recombination deficiency in pancreatic cancer: A systematic review and prevalence meta-analysis","volume":"39","author":"Casolino","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.dld.2026.02.020_bib0050","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1053\/j.seminoncol.2016.09.002","article-title":"Familiar pancreatic cancer","volume":"43","author":"Petersen","year":"2016","journal-title":"Semin Oncol"},{"issue":"28","key":"10.1016\/j.dld.2026.02.020_bib0051","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1200\/JCO.2015.61.6961","article-title":"Assessing the significance of BRCA1 and BRCA2 mutations in pancreatic cancer","volume":"33","author":"Carnevale","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.dld.2026.02.020_bib0052","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","article-title":"Platinum resistance: the role of DNA repair pathways","volume":"14","author":"Martin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dld.2026.02.020_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102262","article-title":"Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants","volume":"100","author":"Macchini","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.dld.2026.02.020_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100238","article-title":"Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey","volume":"6","author":"Orsi","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.dld.2026.02.020_bib0055","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41416-022-02086-w","article-title":"Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)","volume":"877\u2013885","author":"Orsi","year":"2023","journal-title":"Br J Canc"},{"key":"10.1016\/j.dld.2026.02.020_bib0056","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","author":"Golan","year":"2019","journal-title":"New Engl J Medicine"},{"issue":"3","key":"10.1016\/j.dld.2026.02.020_bib0057","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70364","article-title":"Real-world impact of olaparib exposure in advanced pancreatic cancer patients harboring germline BRCA1\/2 pathogenic variants","volume":"14","author":"Milella","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.dld.2026.02.020_bib0058","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II study of maintenance Rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.dld.2026.02.020_bib0059","first-page":"1768","article-title":"The KRAS G12D inhibitor MRTX1133 achieves tumor regression in preclinical models of pancreatic cancer","volume":"12","author":"Hallin","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.dld.2026.02.020_bib0060","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C\u2013Mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"New Engl J Medicine"},{"key":"10.1016\/j.dld.2026.02.020_bib0061","first-page":"519","article-title":"Sotorasib in KRAS G12C\u2013mutated pancreatic cancer: updated results from CodeBreaK100","volume":"41","author":"Pant","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.dld.2026.02.020_bib0062","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17152453","article-title":"Treatment of KRAS-mutated pancreatic cancer: new hope for the patients?","volume":"17","author":"Krupa","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.dld.2026.02.020_bib0063","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion\u2013positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"New Engl J Medicine"},{"key":"10.1016\/j.dld.2026.02.020_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2026.02.020_bib0065","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.3003","article-title":"Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions","volume":"39","author":"Schram","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2026.02.020_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.dld.2026.02.020_bib0067","doi-asserted-by":"crossref","first-page":"4809","DOI":"10.1038\/s41598-023-31051-7","article-title":"Circulating tumor DNA in molecular assessment feasibly predicts early progression of pancreatic cancer that cannot be identified via initial imaging","volume":"13","author":"Watanabe","year":"2023","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.dld.2026.02.020_bib0068","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41416-021-01624-2","article-title":"Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials","volume":"126","author":"Pietrasz","year":"2022","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.dld.2026.02.020_bib0069","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/SLA.0000000000006468","article-title":"PANACHE01-PRODIGE48 group. New biomarkers to define a biological borderline situation for pancreatic adenocarcinoma: results of an ancillary study of the PANACHE01-PRODIGE48 trial","volume":"280","author":"Pinson","year":"2024","journal-title":"Ann Surg"},{"issue":"12","key":"10.1016\/j.dld.2026.02.020_bib0070","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12142","article-title":"Extracellular vesicles are the primary source of blood-borne tumour-derived mutant KRAS DNA early in pancreatic cancer","volume":"10","author":"Hagey","year":"2021","journal-title":"J Extracell Vesicles"},{"issue":"5","key":"10.1016\/j.dld.2026.02.020_bib0071","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1053\/j.gastro.2022.06.090","article-title":"An exosome-based transcriptomic signature for noninvasive, early detection of patients with pancreatic ductal adenocarcinoma: A multicenter cohort study","volume":"163","author":"Nakamura","year":"2022","journal-title":"Gastroenterology"},{"issue":"785","key":"10.1016\/j.dld.2026.02.020_bib0072","doi-asserted-by":"crossref","first-page":"eadq3110","DOI":"10.1126\/scitranslmed.adq3110","article-title":"Early detection of pancreatic cancer by a high-throughput protease-activated nanosensor assay","volume":"17","author":"Montoya Mira","year":"2025","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.dld.2026.02.020_bib0073","doi-asserted-by":"crossref","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","author":"Moffit","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.dld.2026.02.020_bib0074","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.dld.2026.02.020_bib0075","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2018.08.033","article-title":"Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features","volume":"155","author":"Puleo","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.dld.2026.02.020_bib0076","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","article-title":"Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial","volume":"24","author":"Aung","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.dld.2026.02.020_bib0077","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.trsl.2024.08.002","article-title":"Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort","volume":"273","author":"Lansberg","year":"2024","journal-title":"Transl Res"},{"issue":"1","key":"10.1016\/j.dld.2026.02.020_bib0078","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/1078-0432.CCR-19-1467","article-title":"Purity independent subtyping of tumors (PurIST), A clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer","volume":"26","author":"Rashid","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.dld.2026.02.020_bib0079","doi-asserted-by":"crossref","first-page":"4901","DOI":"10.1158\/1078-0432.CCR-19-3724","article-title":"GATA6 Expression distinguishes classical and basal-like subtypes in advanced pancreatic cancer","volume":"26","author":"O'Kane","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2025","key":"10.1016\/j.dld.2026.02.020_bib0080","article-title":"NeoPancONE: GATA6 expression as a predictor of benefit to peri-operative modified FOLFIRINOX in resectable pancreatic adenocarcinoma (r-PDAC): A multicentre phase II study","volume":"4011","author":"MCLaughlin","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.dld.2026.02.020_bib0081","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1053\/j.gastro.2024.05.032","article-title":"Organoids for functional precision medicine in advanced pancreatic cancer","volume":"167","author":"Boil\u00e8ve","year":"2024","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.dld.2026.02.020_bib0082","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.annonc.2020.10.601","article-title":"A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma","volume":"32","author":"Nicolle","year":"2021","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.dld.2026.02.020_bib0083","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1200\/JCO.22.02668","article-title":"Prediction of adjuvant gemcitabine sensitivity in resectable pancreatic adenocarcinoma using the GemPred RNA signature: an ancillary study of the PRODIGE-24\/CCTG PA6 clinical trial","volume":"42","author":"Nicolle","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.dld.2026.02.020_bib0084","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/j.gastro.2022.11.035","article-title":"A transcriptomic-based tool to predict gemcitabine sensitivity in advanced pancreatic adenocarcinoma","volume":"164","author":"Fraunhoffer","year":"2023","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.dld.2026.02.020_bib0085","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.annonc.2024.06.010","article-title":"Development and validation of AI- assisted transcriptomic signatures to personalize adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma","volume":"35","author":"Fraunhoffer","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.dld.2026.02.020_bib0086","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102858","article-title":"Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer","volume":"57","author":"Nicolle","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.dld.2026.02.020_bib0087","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1437200","article-title":"Development of transcriptomic tools for predicting the response to individual drug of the mFOLFIRINOX regimen in patients with metastatic pancreatic cancer","volume":"14","author":"Fraunhoffer","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.dld.2026.02.020_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102858","article-title":"Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer","volume":"57","author":"Nicolle","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.dld.2026.02.020_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102973","article-title":"Medical management of pancreatic cancer: from personalization to broadening treatment strategies","volume":"138","author":"Dusetti","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.dld.2026.02.020_bib0090","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","article-title":"Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism","volume":"149","author":"Ying","year":"2012","journal-title":"Cell"},{"issue":"7443","key":"10.1016\/j.dld.2026.02.020_bib0091","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12040","article-title":"Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway","volume":"496","author":"Son","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.dld.2026.02.020_bib0092","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.celrep.2019.09.056","article-title":"Glutamine anabolism plays a critical role in pancreatic cancer by coupling carbon and nitrogen metabolism","volume":"29","author":"Bott","year":"2019","journal-title":"Cell Rep"},{"issue":"12","key":"10.1016\/j.dld.2026.02.020_bib0093","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.annonc.2024.08.2339","article-title":"First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration","volume":"35","author":"Rodon","year":"2024","journal-title":"Ann Oncol"},{"issue":"36","key":"10.1016\/j.dld.2026.02.020_bib0094","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1200\/JCO.2015.62.8719","article-title":"Randomized phase ib\/II study of Gemcitabine Plus Placebo or Vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer","volume":"33","author":"Catenacci","year":"2020","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.dld.2026.02.020_bib0095","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of pegvorhyaluronidase Alfa with Nab-Paclitaxel plus Gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.dld.2026.02.020_bib0096","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/path.5224","article-title":"Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma","volume":"248","author":"Neuzillet","year":"2019","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.dld.2026.02.020_bib0097","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/path.6011","article-title":"Periostin- and podoplanin-positive cancer-associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma","volume":"258","author":"Neuzillet","year":"2022","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.dld.2026.02.020_bib0098","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.ccell.2021.02.007","article-title":"Type I collagen deletion in \u03b1sma+myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer","volume":"39","author":"Chen","year":"2021","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.dld.2026.02.020_bib0099","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"Ozdemir","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.dld.2026.02.020_bib0100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41416-019-0479-5","article-title":"Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features","volume":"121","author":"Karamitopoulou","year":"2019","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.dld.2026.02.020_bib0101","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"issue":"2","key":"10.1016\/j.dld.2026.02.020_bib0102","article-title":"Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)","volume":"12","author":"Callahan","year":"2024","journal-title":"J Immunother"},{"issue":"10","key":"10.1016\/j.dld.2026.02.020_bib0103","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without Tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: A phase 2 randomized clinical trial","volume":"5","author":"O'Reilly","year":"2019","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.dld.2026.02.020_bib0104","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10637-017-0525-1","article-title":"Ib\/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma","volume":"36","author":"Weiss","year":"2018","journal-title":"Invest new drugs"},{"key":"10.1016\/j.dld.2026.02.020_bib0105","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s44276-023-00028-4","article-title":"A phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer","volume":"2","author":"Morizane","year":"2024","journal-title":"BJC Rep"},{"issue":"1","key":"10.1016\/j.dld.2026.02.020_bib0106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.dld.2026.02.020_bib0107","doi-asserted-by":"crossref","first-page":"6286","DOI":"10.1158\/1078-0432.CCR-13-1320","article-title":"A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma","volume":"19","author":"Beatty","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.dld.2026.02.020_bib0108","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padron","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.dld.2026.02.020_bib0109","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1470-2045(20)30532-5","article-title":"CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study","volume":"22","author":"O\u2019Hara","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8056","key":"10.1016\/j.dld.2026.02.020_bib0110","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.dld.2026.02.020_bib0111","unstructured":"Pancreatic adenocarcinoma signature stratification for treatment (PASS-01). ClinicalTrials.gov ID NCT04469556"},{"key":"10.1016\/j.dld.2026.02.020_bib0112","unstructured":"PRIMUS 001: a study looking at two different chemotherapy regimens in patients with metastatic pancreatic cancer. ClinicalTrials.gov ID NCT04151277"},{"key":"10.1016\/j.dld.2026.02.020_bib0113","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1200\/JCO-25-00436","article-title":"PASS-01: randomized Phase II trial of modified FOLFIRINOX versus Gemcitabine\/Nab-Paclitaxel and molecular correlatives for previously untreated metastatic pancreatic cancer","author":"Knox","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826003002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865826003002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:26:27Z","timestamp":1777620387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865826003002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":113,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1590865826003002"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2026.02.020","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toward precision chemotherapy in pancreatic ductal adenocarcinoma: molecular, transcriptomic and clinical determinants","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2026.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}